Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma.
Harada E, Serada S, Fujimoto M, Takahashi Y, Takahashi T, Hara H, Nakatsuka R, Sugase T, Nishigaki T, Saito Y, Hiramatsu K, Nojima S, Mitsuo R, Ohkawara T, Morii E, Mori M, Doki Y, Kaneda Y, Naka T.
Harada E, et al. Among authors: serada s.
Oncotarget. 2017 Apr 11;8(15):24741-24752. doi: 10.18632/oncotarget.15799.
Oncotarget. 2017.
PMID: 28445969
Free PMC article.